Tuesday, May 8, 2012
NovaDigm Therapeutics Inc., of Grand Forks, N.D., reported Phase I data showing a single dose of NDV-3, a prophylactic vaccine containing recombinant Als3, a surface adhesion/invasion from Candida albicans, was safe and well tolerated, with or without alum adjuvant, and induced strong antibody and T-cell immune responses.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.